Melanoma Education
Melanoma treatment spans immunotherapy combinations, targeted therapy for BRAF-mutant disease, and expanding adjuvant and neoadjuvant options. Knowledge Med sessions help community providers navigate evolving treatment algorithms through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing melanoma face evolving treatment decisions that interactive, independently reviewed education can help address.
- Selecting between immunotherapy combinations and targeted therapy in BRAF-mutant disease
- Managing immune-related adverse events across combination regimens
- Identifying patients for adjuvant and neoadjuvant immunotherapy
- Treating patients who progress on anti-PD-1 therapy
What Sessions Cover
Knowledge Med Melanoma sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy in advanced melanoma: nivolumab-ipilimumab and beyond
- BRAF/MEK inhibitor therapy: sequencing with immunotherapy
- Adjuvant and neoadjuvant immunotherapy: patient selection and duration
- Managing immunotherapy resistance and subsequent therapy options
Interactive Melanoma Sessions
Case Simulations
Work through realistic melanoma patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key Melanoma clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a Melanoma Session
Third-party, non-promotional melanoma education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session